Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1283 | Duodenal biopsy Wiki | 0.71 |
| drug1010 | Completion of survey after peak of pandemic Wiki | 0.71 |
| drug2628 | Norovirus Bivalent (GI.1 / GII.4) Vaccine（low） Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1009 | Completion of pre-pandemic survey Wiki | 0.71 |
| drug2627 | Norovirus Bivalent (GI.1 / GII.4) Vaccine（high） Wiki | 0.71 |
| drug1008 | Completion of post telemedicine encounter survey Wiki | 0.71 |
| drug1174 | Deep Breathing training Wiki | 0.71 |
| drug3513 | Saliva Wiki | 0.71 |
| drug1005 | Compassion focused intervention Wiki | 0.71 |
| drug2629 | Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle） Wiki | 0.71 |
| drug263 | Aluminum adjuvant Wiki | 0.71 |
| drug2620 | Normal saline Wiki | 0.29 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D005759 | Gastroenteritis NIH | 0.50 |
| D003141 | Communicable Diseases NIH | 0.05 |
| D007239 | Infection NIH | 0.03 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
The primary objective in this study is to establish a list of host cellular proteins that mediate norovirus infection. Norovirus is one of the most common pathogens attributed to diarrheal diseases from unsafe food. It is also the primary cause of mortality among young children and adults in foodborne infections. Norovirus is not just a foodborne burden. In a recent meta-analysis, norovirus accounts for nearly one-fifth of all causes of (including person-to-person transmission) acute gastroenteritis in both sporadic and outbreak settings and affects all age groups. Undoubtedly, norovirus is of paramount public health concern in both developed and developing countries. Research efforts to better understand norovirus pathobiology will be necessary for targeted intervention. From Middle East respiratory syndrome coronavirus to Zika virus, efforts to identify host factors important for mediating virus infection has always been a research priority. Such information will shed light on potential therapeutic targets in antiviral intervention. Norovirus virus-host interaction studies have been hampered by the lack of a robust cell culture model in the past 20 years. In 2016, norovirus has finally been successfully cultivated in a stem cell-derived three-dimensional human gut-like structure called enteroid or mini-gut. In this study, intestinal stem cells will be isolated from duodenal biopsies collected from participants, followed by differentiation into mini-guts. Genome-wide genetic screening for host essential and restrictive factors will be performed on infected mini-guts by knockout CRISPR and gain-of-function CRISPR SAM, respectively. Shortlisted candidates will undergo preliminary functional validation in cell lines. These data will provide insights into potential therapeutic targets against norovirus infection.
Description: Viability of enteroids as determined by microscopy
Measure: Establishment of human intestinal stem cell-derived enteroids Time: An average of three monthsA total of 450 subjects were enrolled, divided into four age groups, including 18-59 years, 6-17 years, 3-5 years, and 6-35 months. There are three types of the test vaccine component in each age group. A total of 30 people in each dose group were vaccinated with the test vaccine or placebo 1 or placebo 2, respectively, in a ratio of 3: 1: 1. The 18-59-year-old, 6-17-year-old, and 3-5-year-old age groups were vaccinated 2 times at a time interval of 28 days. The 6-35 month age group is divided into two groups, Group 1 is inoculated with 2 doses interval of 28 days each, and Group 2 is inoculated with 3 doses interval of 28 days.
Description: Active AE: Local and systemic adverse reactions occurring within 0-7 days after each dose of vaccination
Measure: All active AEs within 0-7 days after each dose Time: 7 daysDescription: Adverse events other than active AE include solicitation adverse events reported in addition to the specified solicitation time window
Measure: All non-active collection AEs within 0-28（30） days after each dose Time: 28（30） daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports